Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12528533 | 1.00 | PDE8B (0.47) | PDE8BATMKDM1AHSD17B10MAPT | |
| SCHEMBL25936315 | 1.00 | PDE8B (0.47) | PDE8BATMKDM1AHSD17B10MAPT | |
| SCHEMBL3576321 | 0.95 | HSD17B10 (0.49) | PDE8BATMHSD17B10MAPTALDH1A1 | |
| SCHEMBL6899788 | 0.95 | HSD17B10 (0.49) | PDE8BATMHSD17B10MAPTALDH1A1 | |
| SCHEMBL1467517 | 0.95 | HSD17B10 (0.49) | PDE8BATMHSD17B10MAPTALDH1A1 | |
| Formic Acid SCHEMBL30817776 | 0.94 | PDE8B (0.44) | PDE8BATMKDM1AHSD17B10MAPT | |
| SCHEMBL24121385 | 0.88 | ATM (0.42) | ATMHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19158003 | 0.88 | ATM (0.42) | ATMHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2687901 | 0.88 | ATM (0.60) | PDE8BATMKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL20828126 | 0.88 | ATM (0.60) | PDE8BATMKDM1AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| CN-112566906-B | Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | 多曼治疗学公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-116867758-A | IRAK degradation agents and uses thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116406267-A | Bicyclic propyl methyl derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116332873-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| CN-107949558-B | Muscarinic agonists | 赫普泰雅治疗有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-27 | — | — | US | disclosed |
| EP-2821402-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| CN-101252929-A | G protein-coupled receptor agonists | PROSIDION LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | BOWEN J PHILLIP (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2003061598-A2 | SOLENOPSIN A, B AND ANALOGS AS NOVEL ANGIOGENESIS INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | PDE8B 600/4885ATM 4476/4885KDM1A 198/4885 |
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | PDE8B 803/4885ATM 3687/4885KDM1A 4672/4885 |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | VEGFA, TEK, FLT1 | PDE8B 2801/4885ATM 3280/4885KDM1A 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.